
ImVitro provides EMBRYOLY, an AI-powered SaaS platform that automates embryo management to improve IVF lab efficiency and outcomes. The platform uses machine learning models trained on a large embryology database and integrates with time‑lapse microscopes to analyze embryo imagery and deliver real-time performance tracking and administrative automation. ImVitro is a medical device developer and the product is regulated for clinical use (CE marking, ISO 13485). Customers are IVF clinics and laboratories across Europe seeking to standardize embryo evaluation and increase pregnancy rates.

ImVitro provides EMBRYOLY, an AI-powered SaaS platform that automates embryo management to improve IVF lab efficiency and outcomes. The platform uses machine learning models trained on a large embryology database and integrates with time‑lapse microscopes to analyze embryo imagery and deliver real-time performance tracking and administrative automation. ImVitro is a medical device developer and the product is regulated for clinical use (CE marking, ISO 13485). Customers are IVF clinics and laboratories across Europe seeking to standardize embryo evaluation and increase pregnancy rates.
Product: EMBRYOLY — AI-powered SaaS for embryo management and evaluation
Regulatory status: Medical device regulated for clinical use (CE marking, ISO 13485)
Founded: 2019
HQ: Paris, France
Recent funding: Seed ~ $2.5M (Dec 2022)
In vitro fertilization (IVF) embryology workflow inefficiencies and variability in embryo evaluation
2019
Biotechnology
2500000
Participating investors listed include MMC Ventures, Fly Ventures, Compound, Tiny Supercomputer Investment Company and others
“Multiple early-stage VCs participated (e.g., LDV Capital, MMC Ventures, Fly Ventures, Compound, Tiny Supercomputer Investment Company)”